From this Monday, October 18 to Friday, October 22, people who have their complete vaccination schedule and who have not been inoculated with Sinovac will be included.
The Ministry of Health (Minsal) detailed the schedule of booster vaccination for the people who were immunized with complete schemes other than Sinovac until May 9, 2021, but for those under 55 years of age.
These are the people who were inoculated with doses of Cansino, Janssen, Pfizer, AstraZeneca, Generium, Moderna, Sinopharm and vaccines in clinical studies; and people with validation of vaccines abroad.
afp
–
Read Also>
YouTube will remove videos with anti-vaccine content
–
The process will start from Monday 18 and for all purposes the requirement will be have completed their vaccination schedule until May 9, 2021.
On Monday, October 18, it will be the turn of the people of between 49 and 54 years; the Tuesday 19 people from between 44 and 48 years; the Wednesday 20 The same will happen with the people of between 40 to 43 yearss; Thursday 21 It will be an opportunity for the people of between 36 and 39 years; and finally on Friday 22, it will be the turn of the people between 18 to 35 years.
Also, during the week, the same group of people will be inoculated (under 55 years old) but what they were immunized with complete scheme of Sinovac until the June 13, 2021.
It is so on Monday, October 18 it will be the turn of the people of between 49 and 54 years; the Tuesday 19 people from between 44 and 48 years; the Wednesday 20 The same will happen with the people of between 40 to 43 yearss; Thursday 21 It will be an opportunity for the people of between 36 and 39 years; and finally on Friday 22, it will be the turn of the people between 18 to 35 years.
Another group that will receive a booster vaccination will be those over 55 years old with a complete schedule of any vaccine, up to June 13th (Cansino, Janssen, Pfizer, AstraZeneca, Generium, Modern, Sinovac, Sinopharm)
In addition, this applies to immunocompromised people from the age of 12. That is, those with solid organ transplantation, hematopoietic precursors, with cancer in treatment, with autoimmune diseases in biological treatments / small molecules and dialysates (heme or peritoneum).
– .